Lifeclean International
LifeClean International develops, manufactures and sells desinfection, decontamination and premium cleaning products through a group structure centered on LifeClean and Kempartner Ocean AB. The business serves regulated end markets in Europe and selected international markets, with production in Vadstena and a mix of own-brand sales, private label manufacturing and licensing arrangements.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueRegulated high-level desinfection products used in healthcare and other controlled environments.
Products and solutions for removing PFAS from contaminated surfaces and systems.
Own-brand environmentally profiled detergents, dish and cleaning products.
Contract manufacturing of chemical products for partners under their brands.
Licenses that allow partners to produce and commercialize LifeClean technology in defined geographies.
Customers
LifeClean sells to healthcare and other regulated environments where desinfection and sanitation are system-critical rather than optional. It also serves industrial customers, brand partners and retail consumers through private label, own-brand channels and webshops. The customer base is split between professional buyers that need documented performance and consumer channels that value environmentally profiled cleaning products.
Buy desinfection products for continuous use in medically regulated environments where reliability and documentation matter.
Buy hygiene and biosafety solutions for short-cycle production environments.
Buy PFAS decontamination products for contaminated equipment, surfaces and systems.
Buy contract-manufactured chemical products produced at Kempartner Ocean AB's facility.
Buy own-brand detergents, dish and cleaning products through stores and webshops.
Strategy
LifeClean's strategy is to build value through focused market selection, disciplined resource allocation and partner-based scaling. It prioritizes regulated use cases where desinfection and remediation are structural needs, then expands through local partners and licensing rather than direct sales alone. The approach is designed to improve market access while preserving traceability, compliance and control over product dossiers.
Local partners provide distribution, regulatory know-how and faster implementation.
Licensing supports geographic scale with limited capital tied up in operations.
Healthcare, agriculture and remediation demand documented performance and recurring need.
Geography
LifeClean is headquartered in Uddevalla, Sweden, with production activities in Vadstena through Kempartner Ocean AB. The company describes Europe as a key market because of regulatory requirements, while also pursuing licensing and commercialization opportunities outside Europe. Its reported market focus includes Sweden, broader Europe, North America and Asia for PFAS-related applications.
Risks
LifeClean is exposed to regulatory, market and supplier risks because its products operate in tightly controlled chemical and biocidal environments. The business also depends on successful commercialization through partners and on continued access to funding and working capital, while PFAS remediation and desinfection markets can be slow to adopt new solutions. Changes in rules, patent outcomes or partner execution could materially affect sales opportunities and product rollout.
- Liquidity and financing riskImpact: HighLikelihood: Medium
The company has relied on external funding to support operations and growth initiatives.
Exposure: Corporate level
- Regulatory compliance riskImpact: HighLikelihood: Low
Products must meet biocidal, chemical and medical-device related rules in multiple jurisdictions.
Exposure: Europe and other active markets
- Intellectual property riskImpact: HighLikelihood: Low
Patent applications may not be granted and competitors may infringe or copy formulations.
Exposure: PFAS remediation and desinfection technology
- Partner execution riskImpact: MediumLikelihood: Medium
The model relies on distributors, licensees and local partners to commercialize products.
Exposure: International expansion
- Market adoption riskImpact: MediumLikelihood: Medium
New remediation and desinfection solutions can face long qualification cycles and slow uptake.
Exposure
Accounting
Judgemental itemsDifferent business lines may recognize revenue at delivery, over time or under license terms.
Impact: Affects timing of reported sales across product, private label and licensing activities
Patents, product dossiers and development assets depend on future commercialization success.
Impact: Could materially affect earnings if recoverability weakens
Contract manufacturing and own-brand products require cost allocation and stock valuation.
Impact: Affects gross profit and working capital
External funding and bridge financing can change cash flow and balance sheet presentation.
Impact: Affects leverage, liquidity and going-concern analysis
Similar listed companies
Publicly listed companies with a comparable business focus.
Lifecore Biomedical, Inc
LFCR · Pharmaceutical Preparations
Lifecore Biomedical is a U.S.-based contract development and manufacturing organization focused on complex sterile injectable products and pharmaceutical-grade hyaluronic acid (HA).
Zone Frontier Inc.
ZONE · Specialty Cleaning, Polishing and Sanitation Preparations
LiqTech International, Inc
LIQT · Misc Industrial & Commercial Machinery & Equipment
LiqTech International is a clean technology company that designs and manufactures ceramic silicon carbide filtration products and automated purification systems.
Lifeloc Technologies, Inc
LCTC · Laboratory Analytical Instruments
Lifeloc Technologies designs and sells portable and fixed-station breath alcohol testing instruments, with a core franchise in evidential breathalyzers for law…
Originclear, Inc.
OCLN · Special Industry Machinery, NEC
Bio Key International Inc
BKYI · Services-Prepackaged Software
BIO-key International develops identity and access management software centered on biometric authentication, multifactor authentication, and…
Last updated: 24/09/2026